Quince Therapeutics, Inc. logo

Quince Therapeutics, Inc.(QNCX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 2 days
PROFIT SINCE LAST BUY
+0.05% ▲
LAST CLOSE
$39.8
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for QNCX

11/13/2026: QNCX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Quince Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, platform-based therapies for rare diseases. The company's main strength is its lead asset, EryDex, which utilizes a specialized drug-delivery system to address high unmet medical needs. Its primary growth opportunity lies in the potential FDA approval and commercialization of this program. The company faces significant risks, including binary clinical outcomes, execution challenges, and the potential for future capital dilution common in pre-revenue biotech. The stock may best suit speculative investors comfortable with the high volatility inherent in clinical-stage companies, and monitoring upcoming clinical trial data remains the most critical task for any investor.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThis is a high-risk, high-reward play dependent entirely on clinical trial outcomes.
Momentum investorWeak fitMomentum is often erratic in pre-revenue biotech and relies on binary clinical news.
Value investorWeak fitThe company lacks stable earnings or cash flow for traditional value assessment.
Dividend investorWeak fitThe company does not pay dividends and reinvests all capital into research.
Low-risk investorWeak fitThe speculative nature and clinical trial risks make this unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stocks often experience sharp swings based on clinical trial data releases.
Valuation riskHighValuation is speculative as it is based on future potential success rather than current earnings.
Competition risk (Rare Disease)Medium / highLarge competitors may develop alternative treatments that could marginalize the company's lead product.
Business qualityMediumThe company is in a transition phase, and its long-term viability depends on the success of its lead asset.
Dividend incomeLow / noneThe company is not expected to generate dividends for the foreseeable future.
Execution riskHighSignificant execution risk exists regarding clinical trial endpoints and FDA regulatory approval.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 32.27M USD
Price to earnings Ratio -
1Y Target Price 75
Price to earnings Ratio -
1Y Target Price 75
Volume (30-day avg) 87.4K shares
Beta 1.33
52 Weeks Range 15.10 - 910.00
Updated Date 11/14/2026
52 Weeks Range 15.10 - 910.00
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -214.01

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 87.22%
Avg. Invested days 26
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
QNCX receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
QNCX has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-47.8%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
QNCX's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
QNCX's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-47.8%, negative) and free-cash-flow growth (-29.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 34.5% (moderate) and 66.8% of outstanding shares are publicly tradable (solid). Insider ownership of 2.90% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Ikarian Capital, LLC 0.36%
Millennium Management LLC 0.35%
Balyasny Asset Management LLC 0.34%
Squadron Capital Management LLC 0.20%
Shay Capital LLC 0.09%

Unit Economics (Per $1K Revenue)

★★★★★
QNCX generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -3.98% (Tax Credit)

Quantitative Style Profile

★★★★★
QNCX has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Rare Disease TherapeuticsClinical-stage drug development, primarily the EryDex system for Ataxia-Telangiectasia.The company does not currently have commercial sales and is betting its future on the success of a single primary drug candidate.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 315.51M
Price to Sales(TTM) -
Enterprise Value 315.51M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 1.44
Shares Outstanding 1.02M
Shares Floating 679.68K
Shares Outstanding 1.02M
Shares Floating 679.68K
Percent Insiders 2.9
Percent Institutions 34.49

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.